Diabetes management technology developer Glooko announced today that it appointed Alfonso “Chito” Zulueta to its board of directors.
Zulueta joins Palo Alto, California-based Glooko’s board having spent more than 30 years with Eli Lilly and Company, serving as a senior executive across an array of global business and commercial units.
According to a news release, Zulueta retired from his roles at Lilly as an executive committee member, corporate officer and president of the company’s international business unit at the end of 2021.
“We are very excited for Chito to join our board and particularly fortunate for his strong understanding of the impact that digital health solutions can have on managing chronic diseases,” Glooko CEO Russ Johannesson said in the release. “He brings a wealth of valuable experience and unique perspectives to our Board, having led successful global healthcare ventures focused on treating diabetes and other diseases. Chito’s appointment comes at a critical time for Glooko, as we continue to broaden our digital therapeutics (DTx) and clinical research businesses.”
Zulueta’s previous roles at Lilly included president of emerging markets, president of Japan, president of global oncology and critical care, VP in charge of U.S. sales and marketing for neuroscience and diabetes/family health and VP of global marketing.
He also serves on the boards of directors at CTS Corporate, Syneos Health and Calidi Biotherapeutics.
“This is a compelling time to join the Glooko board as the company expands its offerings and commercial footprint,” Zulueta said. “Glooko is rapidly increasing its market relevance and is driving real innovation through its digital health solutions, serving more patients and healthcare professionals globally. I’m excited to leverage my experience and insights to help Glooko accelerate this growth and evolution.”